Cargo of small extracellular vesicles from neuronal origin shows progression of dementia in individuals with Down syndrome

Introduction: Individuals with Down syndrome (DS) are at an ultra-high risk of developing Alzheimer's disease (AD). Diagnosis of AD onset in people with DS can be challenging due to the variable degrees of intellectual disability and cognitive impairment among individuals. Methods: Plasma sampl...

Descripción completa

Detalles Bibliográficos
Autores: Ledreux, A, Carmona-Iragui, M, Videla, L, Benejam, B, Barroeta, I, Lleó, A, Alcolea, D, Fortea, J
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p19821
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19821
Access Level:acceso abierto
Palabra clave:Alzheimer's disease
amyloid-beta
biomarker
dementia
Down syndrome
extracellular vesicle
neurofilament-light
phosphorylated Tau
Descripción
Sumario:Introduction: Individuals with Down syndrome (DS) are at an ultra-high risk of developing Alzheimer's disease (AD). Diagnosis of AD onset in people with DS can be challenging due to the variable degrees of intellectual disability and cognitive impairment among individuals. Methods: Plasma samples from individuals with DS diagnosed with AD dementia (n = 33), prodromal AD (n = 31), or cognitively stable (n = 43) were enriched for neuron-derived extracellular vesicles (NDEV) using immunocapture with the L1CAM antibody. We used single-molecule array technology to quantify amyloid-beta (A beta) peptides, Tau, phosphorylated Tau, neurofilament light chain (NfL), and synaptosomal-associated protein 25 (SNAP25) across diagnostic groups. Results: NDEV levels of A beta 40, A beta 42, Tau, pTauT181, pTauT231, NfL, and SNAP25 were significantly higher in people with DS diagnosed with prodromal AD compared to those with no cognitive decline. Middle-aged or older women had higher levels of NDEV biomarkers compared to males. Discussion: NDEV biomarker levels can inform on the onset of AD in individuals with DS.

Similares en LA Referencia